BRIEF—Luye wins China approval for Seroquel XR

Luye Pharma has been granted approval in China for Seroquel XR (quetiapine fumarate) for a new indication. The drug may now be marketed in the treatment of depression arising from bipolar disorder.

The drug has been marketed in more than 80 countries and was picked up by Luye in  a deal with AstraZeneca relating to 51 countries and regions, including China.

Several other CNS products are being developed by Luye in China and overseas.